Hørsholm, Denmark – September 20, 2022
Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election of Henriette Dræbye Rosenquist and Arndt Schottelius as new independent members of the Board of Directors as of September 19, 2022.
Henriette Dræbye Rosenquist, a Danish citizen, has more than 25 years of experience from commercial and general management leadership roles in the global pharmaceutical industry, including Abbott Laboratiories and Pfizer. Henriette has experience as President and Managing Director of Pfizer France and board member of the Association of American pharmaceutical companies. Previously, Henriette was chairman of the Danish Association of the Pharmaceutical Industry (LIF) and board member of the Danish Confederation of Industry (DI).
Arndt Schottelius, MD PhD, a German citizen, is an internationally experienced executive scientific, clinical and business development leader, with more than 25 years R&D leadership experience from Schering (Germany), Berlex Laboratories (US), Genentech (US), and from Morphosys (Germany) and Kymab (UK) where he was a member of the Management Board and instrumental in building and advancing their proprietary portfolios. Arndt is currently Chief Scientific Officer and member of the Management Board of Affimed, a German-based clinical-stage immuno-oncology company, listed on Nasdaq.
Jacob Jelsing, Chairman of Gubra, said: “I am very pleased to welcome these two highly capable and experienced professionals to the board of directors of Gubra. They each bring competencies and experiences, which are highly relevant for the next phase of Gubra’s growth journey. Henriette brings an extremely strong commercial and general management background from large global biopharmaceutical companies, while Arndt, in addition to his convincing scientific and development profile, also brings experience from executive management of several listed companies.”
Henriette Dræbye Rosenquist said:
“Gubra is a remarkable growth case driven by organic growth as well as milestone payments from scientific partnerships. Gubra is an excellent example of a founder-based gem with strong leadership, great company values and a CSR policy breaking new ground. I am delighted to be part of the board and to contribute to unfolding Gubra’s international growth potential.”
Arndt Schottelius said:
“Gubra’s business model has in a relatively short time secured them a solid portfolio of blue-chip clients among the world’s biggest biotech and pharmaceutical companies. On top of this, Gubra has an interesting pipeline of own discovery projects. I am excited to join the board of such an innovative company and look forward to contributing as a board member to take both the discovery pipeline and the contract research business to the next level.”
In connection with the appointment of the two new, independent board members, current board member since 2016, Steffen Theodor Petersen, has decided to step down from the board.
Jacob Jelsing, Chairman of Gubra, said: “I want to thank Steffen for his invaluable contributions to the company for more than 10 years. Steffen has been instrumental in the formation of several transformative partnerships with key industry players during his years with Gubra.”
After the Extraordinary General Meeting the board of directors now consists of four members:
- Jacob Jelsing, Chair
- Alexander Martensen-Larsen, Vice Chair (independent)
- Henriette Dræbye Rosenquist, independent board member
- Arndt Schottelius, independent board member
Sofia Pitt Boserup
Lead Communication Partner
Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at www.gubra.dk
The post Gubra strengthens Board of Directors with two international appointments appeared first on Gubra.